339 related articles for article (PubMed ID: 18408903)
1. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Rajeswari A; Sabesan M
Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
[TBL] [Abstract][Full Text] [Related]
2. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
3. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fuller RW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
8. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
Finnegan KT; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
[TBL] [Abstract][Full Text] [Related]
10. The role of MAO in MPTP toxicity--a review.
Glover V; Gibb C; Sandler M
J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.
Youngster SK; Nicklas WJ; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B.
Walsh SL; Wagner GC
Synapse; 1989; 3(4):308-14. PubMed ID: 2787063
[TBL] [Abstract][Full Text] [Related]
14. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
[TBL] [Abstract][Full Text] [Related]
15. Selegiline and the prophylaxis of Parkinson's disease.
Sandler M; Willoughby J; Glover V; Gibb C
J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
[TBL] [Abstract][Full Text] [Related]
16. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
[TBL] [Abstract][Full Text] [Related]
18. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):147-56. PubMed ID: 3496637
[TBL] [Abstract][Full Text] [Related]
19. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
[TBL] [Abstract][Full Text] [Related]
20. Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.
Samantaray S; Knaryan VH; Butler JT; Ray SK; Banik NL
J Neurochem; 2008 Mar; 104(5):1309-20. PubMed ID: 18036149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]